Article By:
ChinaBio® Today
Saturday, June 1, 2024 3:20 PM EDT
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in milestones, plus tiered royalties.